Avalo Therapeutics to Join Russell Indices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
Source: seekingalpha
- Index Inclusion: Avalo Therapeutics is set to officially join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index after the close of U.S. equity markets on June 26, 2026, which is expected to enhance its market visibility and potentially attract more investor interest.
- Market Reaction: Despite the potential for short-term stock price increases due to index inclusion, Avalo Therapeutics' shares remain under pressure, with analysts noting that further deterioration in the overall market could lead to continued sell-off pressure.
- Financial Performance: The company reported a GAAP EPS of -$0.98, beating expectations by $0.05, indicating some improvement in financial management, although it remains in a loss position.
- Funding Activity: Avalo successfully priced a $375 million public offering, which will help support its research and operational expenditures, thereby enhancing its viability in the competitive biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTX
Wall Street analysts forecast AVTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.960
Low
25.00
Averages
40.40
High
50.00
Current: 19.960
Low
25.00
Averages
40.40
High
50.00
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avalo Therapeutics to Join Russell Indices
- Index Inclusion: Avalo Therapeutics is set to officially join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index after the close of U.S. equity markets on June 26, 2026, which is expected to enhance its market visibility and potentially attract more investor interest.
- Market Reaction: Despite the potential for short-term stock price increases due to index inclusion, Avalo Therapeutics' shares remain under pressure, with analysts noting that further deterioration in the overall market could lead to continued sell-off pressure.
- Financial Performance: The company reported a GAAP EPS of -$0.98, beating expectations by $0.05, indicating some improvement in financial management, although it remains in a loss position.
- Funding Activity: Avalo successfully priced a $375 million public offering, which will help support its research and operational expenditures, thereby enhancing its viability in the competitive biopharmaceutical market.
See More
Avalo Therapeutics Added to Russell 2000 and 3000 Indices
- Inclusion in Small-Cap Index: Avalo Therapeutics will be added to the Russell 2000® and Russell 3000® indices after the close of U.S. markets on June 26, 2026, marking a significant recognition in the small-cap market that may attract more investor interest.
- Increased Market Coverage: The Russell 3000® index measures approximately 96% of the investable U.S. equity market, and Avalo's inclusion will enhance its visibility in the market, strengthening its competitive position in the biotechnology sector.
- Boosted Investor Confidence: As part of the Russell 2000® index, Avalo is likely to become a focal point for investment managers and institutional investors, potentially driving up its stock price and increasing liquidity.
- Positive Clinical Progress: Avalo's lead asset, abdakibart, recently reported positive topline data in a Phase 2 clinical trial for hidradenitis suppurativa (HS), further solidifying its market position in immune-mediated inflammatory diseases.
See More
Avalo Therapeutics Appoints New Board Member
- New Board Appointment: Avalo Therapeutics has appointed Ron Philips to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry, which is expected to significantly impact the company's strategic execution.
- Extensive Industry Background: Currently serving as executive chair of CREATE Medicines and on the boards of Harmony Biosciences and City Therapeutics, Philips was previously the CEO of Orbital Therapeutics, showcasing his deep expertise in biotechnology.
- Clinical Trial Advancement: Avalo plans to advance its investigational anti-IL-1ß monoclonal antibody Abdakibart (AVTX-009) into a registrational Phase 3 trial in the first half of 2027, marking a significant step in its drug development efforts.
- Stock Price Movement: Avalo closed at $17.83 on Tuesday, up 4.39%, but shares fell 1.51% in after-hours trading to $17.56, indicating cautious market sentiment regarding the new appointment.
See More
Avalo Plans IND Submission for AVTX-010 in H1 2027
- Clinical Advancement: Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody, with plans to submit an IND application in the first half of 2027, aiming to address treatment needs for immune-mediated inflammatory diseases like hidradenitis suppurativa and expand its pipeline.
- Market Demand Response: The development of AVTX-010 is based on the successful Phase 2 data of abdakibart, aiming to enhance patient adherence by extending dosing intervals, thereby meeting the preference for less frequent dosing among patients and physicians, which could strengthen market competitiveness.
- Positive FDA Engagement: Avalo's productive engagement with the FDA provides a streamlined path for clinical trials of AVTX-010, which not only accelerates the product's market entry but may also enhance the company's reputation and position in the biopharmaceutical sector.
- Funding Support: The financing completed in May provides essential funding for the company to advance abdakibart into a pivotal Phase 3 registrational program while laying a solid foundation for the development of AVTX-010, demonstrating the company's confidence in future growth.
See More
Latest Ratings and Outlook from Wall Street
- Optimistic Outlook for SpaceX: Wolfe initiates SpaceX with an outperform rating, highlighting its ability to bring launch costs near zero, creating a competitive moat that could significantly enhance the company's valuation.
- Broadcom Maintains Buy Rating: UBS reiterates its buy rating on Broadcom despite concerns regarding its partnership with Google, suggesting that recent roadmap changes and supply challenges may impact future earnings.
- Williams-Sonoma Upgraded to Buy: Bank of America upgrades Williams-Sonoma from neutral to buy, citing its strong performance in the consumer discretionary sector and expectations of continued market share gains.
- Positive Outlook for Avalo Therapeutics: Bank of America expresses bullish sentiment on Avalo Therapeutics' skin disease treatment, initiating coverage with a buy rating and a $35 price target based on positive clinical trial results.
See More
Avalo Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Avalo Therapeutics reported a Q1 GAAP EPS of -$0.98, exceeding expectations by $0.05, indicating some improvement in financial management despite ongoing losses.
- Cash Flow Status: As of March 31, 2026, the company had $82.0 million in cash, cash equivalents, and short-term investments, with net cash used in operating activities amounting to $17.7 million, reflecting challenges in cash utilization efficiency.
- Successful Financing: Subsequent to March 31, 2026, the company completed an underwritten public offering, raising approximately $405.0 million in net proceeds, significantly enhancing liquidity and supporting future operations.
- Funding Outlook: The current cash and short-term investments are expected to fund operations into 2029, demonstrating Avalo Therapeutics' positive outlook in financial management and future growth planning.
See More
Avalo Therapeutics to Join Russell Indices
- Index Inclusion: Avalo Therapeutics is set to officially join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index after the close of U.S. equity markets on June 26, 2026, which is expected to enhance its market visibility and potentially attract more investor interest.
- Market Reaction: Despite the potential for short-term stock price increases due to index inclusion, Avalo Therapeutics' shares remain under pressure, with analysts noting that further deterioration in the overall market could lead to continued sell-off pressure.
- Financial Performance: The company reported a GAAP EPS of -$0.98, beating expectations by $0.05, indicating some improvement in financial management, although it remains in a loss position.
- Funding Activity: Avalo successfully priced a $375 million public offering, which will help support its research and operational expenditures, thereby enhancing its viability in the competitive biopharmaceutical market.
See More
Avalo Therapeutics Added to Russell 2000 and 3000 Indices
- Inclusion in Small-Cap Index: Avalo Therapeutics will be added to the Russell 2000® and Russell 3000® indices after the close of U.S. markets on June 26, 2026, marking a significant recognition in the small-cap market that may attract more investor interest.
- Increased Market Coverage: The Russell 3000® index measures approximately 96% of the investable U.S. equity market, and Avalo's inclusion will enhance its visibility in the market, strengthening its competitive position in the biotechnology sector.
- Boosted Investor Confidence: As part of the Russell 2000® index, Avalo is likely to become a focal point for investment managers and institutional investors, potentially driving up its stock price and increasing liquidity.
- Positive Clinical Progress: Avalo's lead asset, abdakibart, recently reported positive topline data in a Phase 2 clinical trial for hidradenitis suppurativa (HS), further solidifying its market position in immune-mediated inflammatory diseases.
See More
Avalo Therapeutics Appoints New Board Member
- New Board Appointment: Avalo Therapeutics has appointed Ron Philips to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry, which is expected to significantly impact the company's strategic execution.
- Extensive Industry Background: Currently serving as executive chair of CREATE Medicines and on the boards of Harmony Biosciences and City Therapeutics, Philips was previously the CEO of Orbital Therapeutics, showcasing his deep expertise in biotechnology.
- Clinical Trial Advancement: Avalo plans to advance its investigational anti-IL-1ß monoclonal antibody Abdakibart (AVTX-009) into a registrational Phase 3 trial in the first half of 2027, marking a significant step in its drug development efforts.
- Stock Price Movement: Avalo closed at $17.83 on Tuesday, up 4.39%, but shares fell 1.51% in after-hours trading to $17.56, indicating cautious market sentiment regarding the new appointment.
See More
Avalo Plans IND Submission for AVTX-010 in H1 2027
- Clinical Advancement: Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody, with plans to submit an IND application in the first half of 2027, aiming to address treatment needs for immune-mediated inflammatory diseases like hidradenitis suppurativa and expand its pipeline.
- Market Demand Response: The development of AVTX-010 is based on the successful Phase 2 data of abdakibart, aiming to enhance patient adherence by extending dosing intervals, thereby meeting the preference for less frequent dosing among patients and physicians, which could strengthen market competitiveness.
- Positive FDA Engagement: Avalo's productive engagement with the FDA provides a streamlined path for clinical trials of AVTX-010, which not only accelerates the product's market entry but may also enhance the company's reputation and position in the biopharmaceutical sector.
- Funding Support: The financing completed in May provides essential funding for the company to advance abdakibart into a pivotal Phase 3 registrational program while laying a solid foundation for the development of AVTX-010, demonstrating the company's confidence in future growth.
See More
Latest Ratings and Outlook from Wall Street
- Optimistic Outlook for SpaceX: Wolfe initiates SpaceX with an outperform rating, highlighting its ability to bring launch costs near zero, creating a competitive moat that could significantly enhance the company's valuation.
- Broadcom Maintains Buy Rating: UBS reiterates its buy rating on Broadcom despite concerns regarding its partnership with Google, suggesting that recent roadmap changes and supply challenges may impact future earnings.
- Williams-Sonoma Upgraded to Buy: Bank of America upgrades Williams-Sonoma from neutral to buy, citing its strong performance in the consumer discretionary sector and expectations of continued market share gains.
- Positive Outlook for Avalo Therapeutics: Bank of America expresses bullish sentiment on Avalo Therapeutics' skin disease treatment, initiating coverage with a buy rating and a $35 price target based on positive clinical trial results.
See More
Avalo Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Avalo Therapeutics reported a Q1 GAAP EPS of -$0.98, exceeding expectations by $0.05, indicating some improvement in financial management despite ongoing losses.
- Cash Flow Status: As of March 31, 2026, the company had $82.0 million in cash, cash equivalents, and short-term investments, with net cash used in operating activities amounting to $17.7 million, reflecting challenges in cash utilization efficiency.
- Successful Financing: Subsequent to March 31, 2026, the company completed an underwritten public offering, raising approximately $405.0 million in net proceeds, significantly enhancing liquidity and supporting future operations.
- Funding Outlook: The current cash and short-term investments are expected to fund operations into 2029, demonstrating Avalo Therapeutics' positive outlook in financial management and future growth planning.
See More
